Thus, the synergism of topoisomerase inhibitors and 15d-PGJ2 was not detected in the VHL-negative ccRCC, suggesting that VHL might be involved in the combinational effect of topoisomerase inhibitors and 15d-PGJ2. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.